LONDON – Despite a decade of effort to streamline discovery and development and increase productivity, the projected return on investment (ROI) in R&D at the world’s leading pharmaceutical companies has hit an all-time low, according to the 10th annual analysis by management consultancy Deloitte.

Rarecyte Inc., a Seattle-based company making products for tissue and cell analysis, reported picking up $22 million in a series F financing round led by Healthquest Capital. Also participating in the round were existing investors 5AM Ventures and Ron Seubert, Rarecyte’s founder and chief technology officer. The company plans to use the funds to expand global sales of its instruments and consumables platform in research clinical markets.

PARIS – Biolog-id SAS, specialists in traceability and management of delicate health care products (red blood cells, plasma, platelets and chemotherapy substances), has just raised $33 million from fund managers Xerys Gestion. “Thanks to this new funding, we will be able to roll out our smart traceability solutions worldwide. These are used for managing labile blood products and plasma fractionation,” Jean-Claude Mongrenier, founder and CEO of the Boulogne-Billancourt, France-based company, told BioWorld MedTech.